April Kelly Scott Salama, MD

Associate Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 30 Duke Medicine Circle, 25177 Morris Bldg, Durham, NC 27710
In Their Words

Education and Training

  • Hematology/Oncology, The University of Chicago, 2007 - 2010
  • Internal Medicine, The University of Chicago, 2004 - 2007
  • M.D., University of North Carolina - Chapel Hill, 2004

Grants

Publications

Kennedy, Lucy Boyce, and April K. S. Salama. “A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond.” Jco Oncol Pract 18, no. 5 (May 2022): 353–54. https://doi.org/10.1200/OP.22.00012.

PMID
35196070
Full Text

Nathan, Paul, Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, et al. “Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.” N Engl J Med 385, no. 13 (September 23, 2021): 1196–1206. https://doi.org/10.1056/NEJMoa2103485.

PMID
34551229
Full Text

Dikshit, Anushka, Junqi Lu, Amy E. Ford, Simone Degan, Yingai J. Jin, Huiying Sun, Amanda Nichols, et al. “Potential Utility of Synthetic D-Lactate Polymers in Skin Cancer.” Jid Innovations : Skin Science From Molecules to Population Health 1, no. 3 (September 2021): 100043. https://doi.org/10.1016/j.xjidi.2021.100043.

PMID
34909738
Full Text

Salama, A. K. S., V. Cheshuk, J. Siveke, A. Berrocal, S. E. Abdullah, S. Lockwood, M. L. McCully, and D. Kee. “1014P Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanoma.” In Annals of Oncology, 32:S855–S855. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1398.

Full Text

Sarver, Melissa, Michael C. Brown, Kristen E. Rhodin, April K. S. Salama, and Georgia M. Beasley. “Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.” Hum Vaccin Immunother, July 13, 2021, 1–9. https://doi.org/10.1080/21645515.2021.1943987.

PMID
34254900
Full Text

Kennedy, Lucy, Amanda E. D. Van Swearingen, Jeff Sheng, Dadong Zhang, Xiaodi Qin, Eric S. Lipp, Swaminathan Kumar, et al. “An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).” In Journal of Clinical Oncology, 39:9521–9521. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.9521.

Full Text

DeVito, Nicholas C., Michael Sturdivant, Balamayooran Thievanthiran, Christine Xiao, Michael P. Plebanek, April K. S. Salama, Georgia M. Beasley, et al. “Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy.” Cell Rep 35, no. 5 (May 4, 2021): 109071. https://doi.org/10.1016/j.celrep.2021.109071.

PMID
33951424
Full Text

Johnson, D. B., S. M. Swetter, A. K. S. Salama, and E. Wuthrick. “Cutaneous melanoma: Management of melanoma brain metastases and molecular testing.” In Jnccn Journal of the National Comprehensive Cancer Network, 19:644–47, 2021. https://doi.org/10.6004/jnccn.2021.5021.

Full Text

Swetter, Susan M., John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, et al. “NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.” J Natl Compr Canc Netw 19, no. 4 (April 1, 2021): 364–76. https://doi.org/10.6004/jnccn.2021.0018.

PMID
33845460
Full Text

Beasley, Georgia M., Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin-Ho Jung, et al. “Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma.” J Immunother Cancer 9, no. 4 (April 2021). https://doi.org/10.1136/jitc-2020-002203.

PMID
33875611
Full Text

Pages